A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

January 14, 2026

Study Completion Date

January 14, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

PF-07054894

Oral

DRUG

Placebo

Placebo

Trial Locations (17)

10117

Charité Research Organisation, Berlin

Charité Universitaetsmedizin Berlin - Campus Mitte, Berlin

33609

GCP Clinical Research, Tampa

33615

Tampa Bay Endoscopy Center, Tampa

34741

IHS Health Research, Kissimmee

Kissimmee Endosocpy Center ( Endoscopy Only ), Kissimmee

Orlando Diagnostic Center ( CXR Only ), Kissimmee

52242

University of Iowa, Iowa City

78212

Carta - Clinical Associates In Research Therapeutics Of America, San Antonio

85-231

NZOZ Centrum Medyczne KERmed, Bydgoszcz

30-688

SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow

04-501

Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś, Warsaw

15-704

KLIMED Marek Klimkiewicz, Bialystok

44-190

MZ Badania Slowik Zymla Spolka Jawna, Knurów

82-300

NZOZ Twoje Zdrowie EL Sp. z o. o., Elblag

91-034

Centrum Medyczne Med-Gastr, Lodz

97-300

IRMED, Piotrkow Trybunalski

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY